Alamar Biosciences (ALMR) 10% Owner Ltd. Sells $4M of Stock

On October 26, 2026, Qiming Corporate GP VI, Ltd., a major shareholder, sold 132,524 shares of Alamar Biosciences, Inc. at a price of $30.52 per share. The total value of the transaction was about $4,044,685. This trade reduced Qiming's stake in the company by approximately 7.08%, leaving it with 1,738,295 shares.

ALMR Alamar Biosciences, Inc.

$30.39 ▲ +17.43% past 3 months

1M 3M

Daily close · Oct 26, 2026

Inside Qiming Corporate GP VI's Trade

This sale marks the latest in a series of transactions by Qiming Corporate GP VI. Just days earlier, the firm sold multiple blocks of shares, including 142,004 shares on October 20 and 208,815 shares on October 21. These trades suggest a strategic adjustment in their investment in Alamar Biosciences.

Other Institutional Activity in Alamar Biosciences

Several other institutional investors have been active in Alamar Biosciences recently. Sands Capital Alternatives, LLC grew its holdings by 2,115,463 shares, totaling 4,230,926 shares valued at approximately $135.1 million. Samsara BioCapital, LLC also increased its position, adding 1,240,155 shares to reach 2,480,310 shares worth about $79.2 million. ARK Investment Management, LLC, Braidwell LP, and AllianceBernstein L.P. have similarly bolstered their stakes, contributing to a positive institutional interest in the company.

Alamar Biosciences, Inc. Stock Up 5.1%

As of October 26, 2026, Alamar Biosciences closed at $30.39, while it has recently traded around $31.93, which is about 5.1% above the closing price. The stock is currently below its 52-week high of $39.61 but is significantly above its 52-week low of $18.85, indicating a strong recovery from earlier lows. The recent price is also about 9.8% below the mean analyst target price of $35.40.

Recent Earnings

Alamar Biosciences reported trailing twelve-month revenue of approximately $100.4 million, reflecting a year-over-year growth of 82.1%. However, the company has a negative net margin of 49.5% and an EPS of -1.2, indicating ongoing challenges in profitability. The next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at Alamar Biosciences, Inc.

In addition to the recent sale by Qiming Corporate GP VI, the firm has been active in the market. On October 19, 2026, it sold 75,508 shares at $26.34, followed by a sale of 142,004 shares at $27.89 on October 20, and 208,815 shares at $30.31 on October 21. The firm also sold 133,811 shares at $29.33 on October 22. These transactions indicate a significant reduction in their holdings over a short period.

Analysts Set New Price Targets

On August 11, 2026, Stifel maintained a "Buy" rating on Alamar Biosciences with a price target of $32.00, up from a prior target of $28.00. JP Morgan also maintained an "Overweight" rating with a target of $35.00, increased from $32.00. The consensus among analysts is positive, reflecting confidence in the company's growth potential.

About Alamar Biosciences

Alamar Biosciences, Inc. is a healthcare company based in Fremont, CA, that focuses on developing a proteomic liquid biopsy platform. It aims to enhance early disease detection through its innovative NULISA technology, which detects and quantifies protein biomarkers. Given the recent trading activity, the company is navigating its growth while adjusting to market conditions.

Bottom Line

Investors should keep an eye on Alamar Biosciences as it approaches its next earnings date on November 3, 2026. With ongoing insider sales and institutional interest, the company's market dynamics are evolving, and further developments will be crucial to watch in the coming weeks.